SC 13G/A - NANOVIRICIDES, INC. (0001379006) (Subject)

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.Event Information:EventNanoViricides Presentation at the Biotech Showcase, San FransiscoDay & DateTuesday, January 14, 2025Time, Track & Room2:30pm PT, Yosemite A (Ballroom Level)LocationHilton San Fransisco - Union SquareAnil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline a

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already.This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.In addition to that, in the USA, and globally, there are significant numbers of cases of COVID-19, RSV, and hMPV as expected seasonally, that cause various respiratory syndromes from common colds

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug."Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."WHO has stated "Available virus

SHELTON, CT / ACCESSWIRE / November 15, 2024 / SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).We reported that, as of September 30, 2024, we had cash and cash equivalent current assets balance of approximately $3.87 Million. In addition, we reported approximately $7.36 Million in Net Property and Equipment (P&E) assets (after de

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a corporate update at the Spartan Capital Investors Conference on Monday, November 4, 2024 (today) at 9:45 am. The Conference will be held at the Pierre Hotel in New York City.EventThe Spartan Capital Investors Conference 2024Day & DateMonday, November 4, 2024LocationThe Pierre Hotel, New York, NY, USA.Talk TitleRevolutionizing Antiviral Treatments, Phase 2-Ready, Broad-Spectrum Lead Drug NV-387 Addresses a $2.5 to $4

SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be presenting a talk at the PODD Conference on Monday, October 28th, 2024 at 345pm. The PODD Conference will be held at the Westin Boston Seaport District, MA on October 28 and 29, 2024.EventThe Partnership Opportunities in Drug Delivery (PODD) Conference, 2024Day & DateMonday, October 28, 2024LocationThe Westin Boston Seaport District Hotel, Boston, MA, USA.Talk TitleRevolutionizing Antiviral Treatments, Phase 2-Ready, Ora

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, was interviewed in a podcast by the PODD Conference* host. The podcast was published on October 11, 2024, on PharmaTalkRadio.The interview can be viewed at the PODD website at https://theconferenceforum.org/pharmatalkradio/antiviral-drug-development-how-nanoviricides-is-overcoming-challenges-to-the-current-model.The podcast is also available from the Company's website on the front page (nanoviricides.com).Dr. Diwan explained the nanovir

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, has been invited and will be presenting a talk at the Global AMR Summit, which is being held at the Kimpton Marlowe Hotel, Cambridge, MA, tomorrow, October 9, 2024.AMR, or "Anti-Microbial Resistance" leads to the failure of antibiotic therapy in bacteria, yeasts, fungi, and other human pathogens, a

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm).We reported that, as of June 30, 2024, we had cash and cash equivalent current assets balance of approximately $4.97 Million. In addition, we reported approximately $7.5 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our c

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour").NanoViricides has signed a broad Memorandum of Understanding Agreement (MoU) with TheraCour encompassing all antiviral drugs developments on September 23, 2024, an important step that provides the Company certain intellectual property rights for developing treatments against any viral infections.NV-387, the Company's lead drug, is proving to be a revoluti

4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

4 - NANOVIRICIDES, INC. (0001379006) (Issuer)